Total Payments
$8,815
2024 Payments
$778.99
Companies
41
Transactions
396
Medicare Patients
19,657
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$6,344 (72.0%)
Travel$2,433 (27.6%)
Education$32.35 (0.4%)
Other$6.38 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,344 | 372 | 72.0% |
| Travel and Lodging | $2,433 | 11 | 27.6% |
| Education | $32.35 | 11 | 0.4% |
| Entertainment | $6.38 | 2 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic Vascular, Inc. | $2,521 | 21 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $957.98 | 79 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $697.12 | 53 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $651.92 | 44 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $501.98 | 23 | $0 (2024) |
| Medtronic, Inc. | $477.80 | 2 | $0 (2021) |
| Amgen Inc. | $477.30 | 31 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $349.81 | 23 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $334.66 | 33 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $311.58 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $778.99 | 44 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($160.39) |
| 2023 | $809.65 | 37 | E.R. Squibb & Sons, L.L.C. ($211.04) |
| 2022 | $233.23 | 12 | Boston Scientific Corporation ($87.21) |
| 2021 | $727.14 | 10 | Medtronic, Inc. ($477.80) |
| 2020 | $213.83 | 13 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($75.93) |
| 2019 | $2,262 | 104 | Medtronic Vascular, Inc. ($1,047) |
| 2018 | $2,642 | 90 | Medtronic Vascular, Inc. ($1,345) |
| 2017 | $1,148 | 86 | Novartis Pharmaceuticals Corporation ($238.14) |
All Payment Transactions
396 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: Not Applicable | ||||||
| 11/11/2024 | HemoSonics LLC | QUNATRA QPLUS SYSTEM (Device), QUANTRA QPLUS SYSTEM | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: HEMATOLOGY | ||||||
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $23.66 | General |
| Category: Cardiovascular | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/21/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $91.99 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/09/2024 | HemoSonics LLC | QUNATRA QPLUS SYSTEM (Device), QUANTRA QPLUS SYSTEM | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: HEMATOLOGY | ||||||
| 10/02/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/20/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $14.83 | General |
| Category: Cardiovascular | ||||||
| 09/18/2024 | Philips North America LLC | (CK4) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $23.40 | General |
| Category: Medical Device | ||||||
| 09/13/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $0.35 | General |
| Category: Cardiovascular | ||||||
| 08/28/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $21.32 | General |
| Category: Cardiovascular | ||||||
| 08/26/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $17.42 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 08/21/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/21/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $13.54 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 08/21/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $0.57 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/16/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $16.03 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 08/13/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $16.50 | General |
| Category: Cardiology | ||||||
| 08/02/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/25/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $21.12 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 07/03/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/27/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $19.15 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/26/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $19.77 | General |
| Category: Cardiovascular | ||||||
| 06/26/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $0.74 | General |
| Category: Cardiovascular | ||||||
| 06/21/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $12.73 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 3,612 | 5,575 | $863,596 | $211,980 |
| 2022 | 35 | 5,051 | 8,092 | $1.2M | $317,445 |
| 2021 | 39 | 5,263 | 7,802 | $1.1M | $302,262 |
| 2020 | 36 | 5,731 | 8,469 | $1.1M | $281,558 |
Total Patients
19,657
Total Services
29,938
Medicare Billing
$1.1M
Procedure Codes
149
All Medicare Procedures & Services
149 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 610 | 1,029 | $276,801 | $83,219 | 30.1% |
| 33208 | Insertion of pacemaker and upper and lower heart chamber electrode | Facility | 2023 | 44 | 44 | $76,934 | $17,900 | 23.3% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Facility | 2023 | 301 | 714 | $63,546 | $14,384 | 22.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 131 | 142 | $44,020 | $13,973 | 31.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 264 | 267 | $54,468 | $12,849 | 23.6% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Facility | 2023 | 87 | 521 | $38,554 | $9,754 | 25.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 124 | 125 | $49,625 | $6,812 | 13.7% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Facility | 2023 | 371 | 493 | $29,580 | $6,797 | 23.0% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Facility | 2023 | 102 | 232 | $38,976 | $5,854 | 15.0% |
| 33228 | Removal and replacement of dual lead permanent pacemaker | Facility | 2023 | 20 | 20 | $20,540 | $5,436 | 26.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 268 | 390 | $18,330 | $3,738 | 20.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $12,276 | $3,728 | 30.4% |
| 93289 | Evaluation of single, dual, or multiple lead implantable defibrillator system | Facility | 2023 | 105 | 129 | $14,964 | $3,518 | 23.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 56 | 88 | $9,998 | $3,422 | 34.2% |
| 93454 | Insertion of tube in coronary artery for diagnosis with review by radiologist | Facility | 2023 | 15 | 15 | $10,275 | $2,733 | 26.6% |
| 93307 | Ultrasound of heart | Facility | 2023 | 80 | 80 | $10,000 | $2,435 | 24.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 277 | 354 | $16,284 | $2,238 | 13.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 38 | 38 | $7,296 | $2,179 | 29.9% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 148 | 149 | $19,370 | $2,069 | 10.7% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 17 | 17 | $5,236 | $1,429 | 27.3% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 148 | 149 | $22,350 | $1,410 | 6.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 22 | $4,296 | $1,304 | 30.4% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 42 | 152 | $5,016 | $1,087 | 21.7% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 77 | 77 | $2,772 | $773.08 | 27.9% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 40 | 42 | $3,024 | $753.09 | 24.9% |
About David Gnegy
David Gnegy is a Cardiovascular Disease healthcare provider based in Parkersburg, West Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174591192.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, David Gnegy has received a total of $8,815 in payments from pharmaceutical and medical device companies, with $778.99 received in 2024. These payments were reported across 396 transactions from 41 companies. The most common payment nature is "Food and Beverage" ($6,344).
As a Medicare-enrolled provider, Gnegy has provided services to 19,657 Medicare beneficiaries, totaling 29,938 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 149 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Parkersburg, WV
- Active Since 03/08/2006
- Last Updated 04/18/2022
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1174591192
Products in Payments
- Micra (Device) $1,353
- Attain (Device) $1,297
- ENTRESTO (Drug) $738.57
- LifeVest (Device) $651.92
- ELIQUIS (Drug) $494.81
- XARELTO (Drug) $327.69
- CAMZYOS (Drug) $309.94
- BRILINTA (Drug) $287.78
- JARDIANCE (Drug) $271.52
- PRALUENT (Drug) $266.76
- Corlanor (Drug) $246.60
- Repatha (Biological) $230.70
- LEQVIO (Drug) $219.41
- KENGREAL (Drug) $154.12
- Performa (Device) $150.76
- HeartMate II LVAS (Device) $142.85
- LifeSPARC System (Device) $142.53
- FARXIGA (Drug) $130.40
- Reveal LINQ (Device) $129.98
- TherOx DS2 Console (Device) $115.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Parkersburg
Getachew Zeleke, Md, MD
Cardiovascular Disease — Payments: $9,756
Cardiovascular Disease $9,756
John Mason, Md, MD
Cardiovascular Disease — Payments: $2,743
Cardiovascular Disease $2,743
Dr. Hemant Modi
Cardiovascular Disease — Payments: $2,101
Cardiovascular Disease $2,101
Dr. Michael Avington
Cardiovascular Disease
Cardiovascular Disease